FRAMINGHAM, MA — August 13, 2025 — Leads & Copy — Xenetic Biosciences, Inc. has expanded its strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies. The company ended the quarter with $4.8 million in cash to fund operations.
Xenetic Biosciences (NASDAQ: XBIO) reported its financial results for the second quarter 2025, highlighting the expanded collaboration with The Scripps Research Institute (TSRI) to advance the development program evaluating the combination of systemic DNase I and CAR T-cell therapies. Advancements from collaboration partner PeriNess Ltd. were also announced, including a Clinical Study Agreement to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma.
Patient dosing has commenced in an exploratory clinical study of systemic DNase I in combination with FOLFIRINOX for the first-line treatment of unresectable, locally advanced, or metastatic pancreatic cancer at Bnei Zion Medical Center. The company is also pursuing other strategic collaborations to advance its technology.
According to James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic, the company continues to set a strong foundation to advance systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy across various oncology indications. Xenetic is focused on building momentum across all fronts and driving development toward an IND and Phase 1 clinical trial, working with partners to realize the full potential of its DNase platform technology.
Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preclinical proof-of-concept studies combining DNase I with chemotherapy, immunotherapies, and CAR-T therapy in hematological and solid tumor and metastatic cancer models have been completed, advancing the program to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial.
Net loss for the quarter ended June 30, 2025, was approximately $0.7 million. Research & development expenses decreased by approximately $277,000, or 29.7%, to approximately $0.7 million. General and administrative expenses decreased by approximately $472,000, or 41.8%, to approximately $0.7 million.
The company ended the quarter with approximately $4.8 million in cash.
Xenetic Biosciences, Inc. is focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers. The company’s DNase platform is designed to improve outcomes of existing treatments by targeting neutrophil extracellular traps (NETs) involved in cancer progression. Xenetic is focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
Source: Xenetic Biosciences, Inc.
